Join us for a KOL webinar featuring Charles E. Argoff, MD (Albany Medical College), to discuss the unmet medical need in migraine management today, and a potential role for rofecoxib, a COX-2 selective NSAID, in the treatment landscape.

In addition, the Tremeau Pharmaceuticals management team will discuss their development pipeline, including the company’s Phase 3-ready oral therapy TRM-201 (rofecoxib). Previously marketed as VIOXX, rofecoxib has been shown to have a well-established efficacy profile in multiple indications, including migraine. It is the only COX-2 selective NSAID ever approved in the U.S. to demonstrate a reduced risk of gastrointestinal bleeding versus a traditional NSAID in a controlled trial.

A live Q&A session will follow the formal presentations.